{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:14:59Z","timestamp":1782814499669,"version":"3.54.5"},"reference-count":49,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"1","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Olanzapine (Zyprexa) package labeling includes a warning for hyperglycemia, stating physicians should consider the risks and benefits when prescribing olanzapine to patients with an established diagnosis of diabetes mellitus or having borderline increased blood glucose levels. A case report of olanzapine-associated hyperglycemia in a patient with a history of gestational diabetes mellitus (GDM) is presented and literature review is discussed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Report<\/jats:title><jats:p>A 33-year-old female with a past medical history of bipolar disorder, cocaine and amphetamine use disorder, hypertension, and GDM was initiated on olanzapine 5 mg PO daily which was subsequently titrated to 25 mg daily. On day 15 of admission, she developed signs and symptoms of hyperglycemia, with blood glucose readings &amp;gt;500 mg\/dL. Insulin was initiated, olanzapine was discontinued, and her blood glucose began improving. She was later discharged on ziprasidone 20 mg PO twice daily.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>There have been several case reports published on olanzapine-induced hyperglycemia. This is the first case report to specifically recognize a history of GDM as a potential risk factor for developing olanzapine-associated hyperglycemia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Adverse effect profiles and patient-specific risk factors should be considered when selecting appropriate antipsychotic treatment. Olanzapine may not be an ideal medication choice for a person with a history of GDM; however, if olanzapine is indicated, then close blood glucose monitoring is recommended.<\/jats:p><\/jats:sec>","DOI":"10.9740\/mhc.2022.01.037","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T16:56:08Z","timestamp":1642784168000},"page":"37-44","source":"Crossref","is-referenced-by-count":1,"title":["A case report and literature review of olanzapine-associated hyperglycemia with previous history of gestational diabetes"],"prefix":"10.9740","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3578-8427","authenticated-orcid":true,"given":"Jennifer N.","family":"Alastanos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5414-7081","authenticated-orcid":true,"given":"Devika","family":"Suri","sequence":"additional","affiliation":[{"name":"Clinical Pharmacist, St Joseph's Hospital, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3789-068X","authenticated-orcid":true,"given":"Hayato","family":"DeLellis","sequence":"additional","affiliation":[{"name":"Internal Medicine Clinical Pharmacist, St Joseph's Hospital, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8199-5828","authenticated-orcid":true,"given":"Andrea","family":"Mapugay","sequence":"additional","affiliation":[{"name":"PGY-1 Pharmacy Resident, St Joseph's Hospital, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"2022012116474515400_i2168-9709-12-1-37-b01","unstructured":"Eli Lilly and Company. Zyprexa (olanzapine) tablet [updated 2010 Jan; cited 2021 Feb]. In:DailyMed [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=66ef201f-85eb-44f0-9ef0-1b618c6e0bff"},{"key":"2022012116474515400_i2168-9709-12-1-37-b02","doi-asserted-by":"crossref","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020; 177(9): 868- 72. DOI: 10.1176\/appi.ajp.2020.177901. PubMed PMID: 32867516.","DOI":"10.1176\/appi.ajp.2020.177901"},{"key":"2022012116474515400_i2168-9709-12-1-37-b03","doi-asserted-by":"crossref","unstructured":"Park Y, Hernandez-Diaz S, Bateman BT, Cohen JM, Desai RJ, Patorno E, et al. Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes. Am J Psychiatry. 2018; 175(6): 564- 74. DOI: 10.1176\/appi.ajp.2018.17040393. PubMed PMID: 29730938.","DOI":"10.1176\/appi.ajp.2018.17040393"},{"key":"2022012116474515400_i2168-9709-12-1-37-b04","doi-asserted-by":"crossref","unstructured":"Agrawal Y, Lingala K, Tokala H, Kalavakunta JK. Antipsychotic therapy-induced new onset diabetic ketoacidosis. Am J Ther. 2016; 23(6): e1944- 5. DOI: 10.1097\/MJT.0000000000000375. PubMed PMID: 26741957.","DOI":"10.1097\/MJT.0000000000000375"},{"key":"2022012116474515400_i2168-9709-12-1-37-b05","doi-asserted-by":"crossref","unstructured":"Avella J, Wetli CV, Wilson JC, Katz M, Hahn T. Fatal olanzapine-induced hyperglycemic ketoacidosis. Am J Forensic Med Pathol. 2004; 25(2): 172- 5. DOI: 10.1097\/01.paf.0000127391.85007.f4. PubMed PMID: 15166774.","DOI":"10.1097\/01.paf.0000127391.85007.f4"},{"key":"2022012116474515400_i2168-9709-12-1-37-b06","doi-asserted-by":"crossref","unstructured":"Bettinger TL, Mendelson SC, Dorson PG, Crismon ML. Olanzapine-induced glucose dysregulation. Ann Pharmacother. 2000; 34(7-8): 865- 7. DOI: 10.1345\/aph.19327. PubMed PMID: 10928397.","DOI":"10.1345\/aph.19327"},{"key":"2022012116474515400_i2168-9709-12-1-37-b07","doi-asserted-by":"crossref","unstructured":"Bonanno DG, Davydov L, Botts SR. Olanzapine-induced diabetes mellitus. Ann Pharmacother. 2001; 35(5): 563- 5. DOI: 10.1345\/aph.10280. PubMed PMID: 11346063.","DOI":"10.1345\/aph.10280"},{"key":"2022012116474515400_i2168-9709-12-1-37-b08","doi-asserted-by":"crossref","unstructured":"Fertig MK, Brooks VG, Shelton PS, English CW. Hyperglycemia associated with olanzapine. J Clin Psychiatry. 1998; 59(12): 687- 9. DOI: 10.4088\/jcp.v59n1208c. PubMed PMID: 9921705.","DOI":"10.4088\/JCP.v59n1208c"},{"key":"2022012116474515400_i2168-9709-12-1-37-b09","doi-asserted-by":"crossref","unstructured":"Frise C, Attwood B, Watkinson P, Mackillop L. Life-threatening ketoacidosis in a pregnant woman with psychotic disorder. Obstet Med. 2016; 9(1): 46- 9. DOI: 10.1177\/1753495X15621153. PubMed PMID: 27512491.","DOI":"10.1177\/1753495X15621153"},{"key":"2022012116474515400_i2168-9709-12-1-37-b10","doi-asserted-by":"crossref","unstructured":"Gatta B, Rigalleau V, Gin H. Diabetic ketoacidosis with olanzapine treatment. Diabetes Care. 1999; 22(6): 1002- 3. DOI: 10.2337\/diacare.22.6.1002. PubMed PMID: 10372259.","DOI":"10.2337\/diacare.22.6.1002"},{"key":"2022012116474515400_i2168-9709-12-1-37-b11","doi-asserted-by":"crossref","unstructured":"Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics. 1999; 40(5): 438- 43. DOI: 10.1016\/S0033-3182(99)71210-7. PubMed PMID: 10479950.","DOI":"10.1016\/S0033-3182(99)71210-7"},{"key":"2022012116474515400_i2168-9709-12-1-37-b12","doi-asserted-by":"crossref","unstructured":"Howes OD, Rifkin L. Diabetic keto-acidotic (DKA) coma following olanzapine initiation in a previously euglycaemic woman and successful continued therapy with olanzapine. J Psychopharmacol. 2004; 18(3): 435- 7. DOI: 10.1177\/026988110401800317. PubMed PMID: 15358991.","DOI":"10.1177\/026988110401800317"},{"key":"2022012116474515400_i2168-9709-12-1-37-b13","doi-asserted-by":"crossref","unstructured":"Iwaku K, Otuka F, Taniyama M. Acute-onset type 1 diabetes that developed during the administration of olanzapine. Intern Med. 2017; 56(3): 335- 9. DOI: 10.2169\/internalmedicine.56.7010. PubMed PMID: 28154279.","DOI":"10.2169\/internalmedicine.56.7010"},{"key":"2022012116474515400_i2168-9709-12-1-37-b14","doi-asserted-by":"crossref","unstructured":"Johnson RP, Al-Taher MT, Madlock LE, Guo M, Nasdahl CS. Increasing insulin dose for olanzapine-related diabetes. Am J Psychiatry. 2002; 159(1): 150- 1. DOI: 10.1176\/appi.ajp.159.1.150-a. PubMed PMID: 11772711.","DOI":"10.1176\/appi.ajp.159.1.150-a"},{"key":"2022012116474515400_i2168-9709-12-1-37-b15","doi-asserted-by":"crossref","unstructured":"Lindenmayer JP, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus. Am J Psychiatry. 1999; 156(9): 1471. DOI: 10.1176\/ajp.156.9.1471. PubMed PMID: 10484968.","DOI":"10.1176\/ajp.156.9.1471"},{"key":"2022012116474515400_i2168-9709-12-1-37-b16","doi-asserted-by":"crossref","unstructured":"Kohen I, Gampel M, Reddy L, Manu P. Rapidly developing hyperglycemia during treatment with olanzapine. Ann Pharmacother. 2008; 42(4): 588- 91. DOI: 10.1345\/aph.1K607. PubMed PMID: 18364401.","DOI":"10.1345\/aph.1K607"},{"key":"2022012116474515400_i2168-9709-12-1-37-b17","doi-asserted-by":"crossref","unstructured":"Kumar PNS, Thomas B. Hyperglycemia associated with olanzapine treatment. Indian J Psychiatry. 2011; 53(2): 176- 7. DOI: 10.4103\/0019-5545.82562. PubMed PMID: 21772658.","DOI":"10.4103\/0019-5545.82562"},{"key":"2022012116474515400_i2168-9709-12-1-37-b18","doi-asserted-by":"crossref","unstructured":"Kyriazis IA, Korovesis K, Bashir S, Liakouras A, Partheniou C. Diabetic ketoacidosis and severe dyslipidemia in an adult psychotic man with olanzapine treatment. J Clin Psychopharmacol. 2006; 26(1): 92- 4. DOI: 10.1097\/01.jcp.0000196116.78129.86. PubMed PMID: 16415716.","DOI":"10.1097\/01.jcp.0000196116.78129.86"},{"key":"2022012116474515400_i2168-9709-12-1-37-b19","unstructured":"Muench J, Carey M. Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature. J Am Board Fam Pract. 2001; 14(4): 278- 82. PubMed PMID: 11458971."},{"key":"2022012116474515400_i2168-9709-12-1-37-b20","doi-asserted-by":"crossref","unstructured":"Ober SK, Hudak R, Rusterholtz A. Hyperglycemia and olanzapine. Am J Psychiatry. 1999; 156(6): 970. DOI: 10.1176\/ajp.156.6.970. PubMed PMID: 10360147.","DOI":"10.1176\/ajp.156.6.970"},{"key":"2022012116474515400_i2168-9709-12-1-37-b21","doi-asserted-by":"crossref","unstructured":"Ragucci KR, Wells BJ. Olanzapine-induced diabetic ketoacidosis. Ann Pharmacother. 2001; 35(12): 1556- 8. DOI: 10.1345\/aph.1A157. PubMed PMID: 11793618.","DOI":"10.1345\/aph.1A157"},{"key":"2022012116474515400_i2168-9709-12-1-37-b22","doi-asserted-by":"crossref","unstructured":"Ramankutty G. Olanzapine-induced destabilization of diabetes in the absence of weight gain. Acta Psychiatr Scand. 2002; 105(3): 235- 6; discussion 236-7. DOI: 10.1034\/j.1600-0447.2002.2c257a.x. PubMed PMID: 11939979.","DOI":"10.1034\/j.1600-0447.2002.2c257a.x"},{"key":"2022012116474515400_i2168-9709-12-1-37-b23","doi-asserted-by":"crossref","unstructured":"Rigalleau V, Gatta B, Bonnaud S, Masson M, Bourgeois ML, Vergnot V, et al. Diabetes as a result of atypical anti-psychotic drugs--a report of three cases. Diabet Med. 2000; 17(6): 484- 6. DOI: 10.1046\/j.1464-5491.2000.00296.x. PubMed PMID: 10975220.","DOI":"10.1046\/j.1464-5491.2000.00296.x"},{"key":"2022012116474515400_i2168-9709-12-1-37-b24","doi-asserted-by":"crossref","unstructured":"Roefaro J, Mukherjee SM. Olanzapine-induced hyperglycemic nonketonic coma. Ann Pharmacother. 2001; 35(3): 300- 2. DOI: 10.1345\/aph.10178. PubMed PMID: 11261526.","DOI":"10.1345\/aph.10178"},{"key":"2022012116474515400_i2168-9709-12-1-37-b25","doi-asserted-by":"crossref","unstructured":"Seaburg HL, McLendon BM, Doraiswamy PM. Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature. Pharmacotherapy. 2001; 21(11): 1448- 54. DOI: 10.1592\/phco.21.17.1448.34421. PubMed PMID: 11714220.","DOI":"10.1592\/phco.21.17.1448.34421"},{"key":"2022012116474515400_i2168-9709-12-1-37-b26","doi-asserted-by":"crossref","unstructured":"Selva KA, Scott SM. Diabetic ketoacidosis associated with olanzapine in an adolescent patient. J Pediatr. 2001; 138(6): 936- 8. DOI: 10.1067\/mpd.2001.114016. PubMed PMID: 11391346.","DOI":"10.1067\/mpd.2001.114016"},{"key":"2022012116474515400_i2168-9709-12-1-37-b27","doi-asserted-by":"crossref","unstructured":"Straker D, Mendelowitz A, Karlin L. Near fatal ketoacidosis with olanzapine treatment. Psychosomatics. 2002; 43(4): 339- 40. DOI: 10.1176\/appi.psy.43.4.339. PubMed PMID: 12189265.","DOI":"10.1176\/appi.psy.43.4.339"},{"key":"2022012116474515400_i2168-9709-12-1-37-b28","doi-asserted-by":"crossref","unstructured":"Torrey EF, Swalwell CI. Fatal olanzapine-induced ketoacidosis. Am J Psychiatry. 2003; 160(12): 2241. DOI: 10.1176\/appi.ajp.160.12.2241. PubMed PMID: 14638601.","DOI":"10.1176\/appi.ajp.160.12.2241"},{"key":"2022012116474515400_i2168-9709-12-1-37-b29","doi-asserted-by":"crossref","unstructured":"Tsuchiyama N, Ando H, Ota T, Sakurai M, Takamura T. Modulating effects of olanzapine on the development of diabetic ketoacidosis. Diabet Med. 2004; 21(3): 300- 1. DOI: 10.1111\/j.1464-5491.2004.01113.x. PubMed PMID: 15008848.","DOI":"10.1111\/j.1464-5491.2004.01113.x"},{"key":"2022012116474515400_i2168-9709-12-1-37-b30","doi-asserted-by":"crossref","unstructured":"Van Meter SA, Seaburg H, McLendon B, Doraiswamy PM. Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose. J Clin Psychiatry. 2001; 62(12): 993- 4. DOI: 10.4088\/jcp.v62n1214b. PubMed PMID: 11780883.","DOI":"10.4088\/JCP.v62n1214b"},{"key":"2022012116474515400_i2168-9709-12-1-37-b31","doi-asserted-by":"crossref","unstructured":"Varma MK, Connolly K, Fulton B. Life-threatening hyperglycemia and acidosis related to olanzapine: a case report and review of the literature. J Intensive Care Med. 2007; 22(1): 52- 5. DOI: 10.1177\/0885066606295823. PubMed PMID: 17259569.","DOI":"10.1177\/0885066606295823"},{"key":"2022012116474515400_i2168-9709-12-1-37-b32","doi-asserted-by":"crossref","unstructured":"Waldman JC, Yaren S. Atypical antipsychotics and glycemia: a case report. Can J Psychiatry. 2002; 47(7): 686- 7. DOI: 10.1177\/070674370204700721. PubMed PMID: 12355686.","DOI":"10.1177\/070674370204700721"},{"key":"2022012116474515400_i2168-9709-12-1-37-b33","doi-asserted-by":"crossref","unstructured":"Wilson DR, D'Souza L, Sarkar N, Newton M, Hammond C. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res. 2003; 59(1): 1- 6. DOI: 10.1016\/s0920-9964(01)00331-0. PubMed PMID: 12413635.","DOI":"10.1016\/S0920-9964(01)00331-0"},{"key":"2022012116474515400_i2168-9709-12-1-37-b34","doi-asserted-by":"crossref","unstructured":"Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry. 1998; 44(8): 778- 83. DOI: 10.1016\/s0006-3223(98)00100-0. PubMed PMID: 9798083.","DOI":"10.1016\/S0006-3223(98)00100-0"},{"key":"2022012116474515400_i2168-9709-12-1-37-b35","unstructured":"Wong JOY, Fu JCK, Hung GBK. Olanzapine-induced diabetic ketoacidosis in a Chinese man. Hong Kong Med J. 2007; 13(1): 73- 4. PubMed PMID: 17277396."},{"key":"2022012116474515400_i2168-9709-12-1-37-b36","doi-asserted-by":"crossref","unstructured":"Cernea S, Dima L, Correll CU, Manu P. Pharmacological management of glucose dysregulation in patients treated with second-generation antipsychotics. Drugs. 2020; 80(17): 1763- 81. DOI: 10.1007\/s40265-020-01393-x. PubMed PMID: 32930957.","DOI":"10.1007\/s40265-020-01393-x"},{"key":"2022012116474515400_i2168-9709-12-1-37-b37","doi-asserted-by":"crossref","unstructured":"Holt RIG. Association between antipsychotic medication use and diabetes. Curr Diab Rep. 2019; 19(10): 96. DOI: 10.1007\/s11892-019-1220-8. PubMed PMID: 31478094.","DOI":"10.1007\/s11892-019-1220-8"},{"key":"2022012116474515400_i2168-9709-12-1-37-b38","doi-asserted-by":"crossref","unstructured":"Chen J, Huang X-F, Shao R, Chen C, Deng C. Molecular mechanisms of antipsychotic drug-induced diabetes. Front Neurosci. 2017; 11: 643. DOI: 10.3389\/fnins.2017.00643. PubMed PMID: 29209160.","DOI":"10.3389\/fnins.2017.00643"},{"key":"2022012116474515400_i2168-9709-12-1-37-b39","doi-asserted-by":"crossref","unstructured":"Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The pathophysiology of gestational diabetes mellitus. Int J Mol Sci. 2018; 19(11): 3342. DOI: 10.3390\/ijms19113342. PubMed PMID: 30373146.","DOI":"10.3390\/ijms19113342"},{"key":"#cr-split#-2022012116474515400_i2168-9709-12-1-37-b40.1","unstructured":"Center for Disease Control and Prevention [Internet]. Diabetes risk factors [updated 2021 April 23"},{"key":"#cr-split#-2022012116474515400_i2168-9709-12-1-37-b40.2","unstructured":"cited 2021 May 21]. Available from: http:\/\/www.cdc.gov\/diabetes\/basics\/risk-factors.html"},{"key":"2022012116474515400_i2168-9709-12-1-37-b41","unstructured":"Garrison A. Screening, diagnosis, and management of gestational diabetes mellitus. Am Fam Physician. 2015; 91(7): 460- 7. PubMed PMID: 25884746."},{"key":"2022012116474515400_i2168-9709-12-1-37-b42","doi-asserted-by":"crossref","unstructured":"Wang Z, Wong ICK, Man KKC, Alfageh BH, Mongkhon P, Brauer R. The use of antipsychotic agents during pregnancy and the risk of gestational diabetes mellitus: a systematic review and meta-analysis. Psychol Med. 2021; 51(6): 1028- 37. DOI: 10.1017\/S003329171900401X. PubMed PMID: 31969198.","DOI":"10.1017\/S003329171900401X"},{"key":"2022012116474515400_i2168-9709-12-1-37-b43","doi-asserted-by":"crossref","unstructured":"Dickson RA, Hogg L. Pregnancy of a patient treated with clozapine. Psychiatr Serv. 1998; 49(8): 1081- 3. DOI: 10.1176\/ps.49.8.1081. PubMed PMID: 9712217.","DOI":"10.1176\/ps.49.8.1081"},{"key":"2022012116474515400_i2168-9709-12-1-37-b44","doi-asserted-by":"crossref","unstructured":"Spivak B, Alamy SS, Jarskog LF, Sheitman BB, Lieberman JA. Ziprasidone alternative for olanzapine-induced hyperglycemia. Am J Psychiatry. 2002; 159(9): 1606. DOI: 10.1176\/appi.ajp.159.9.1606. PubMed PMID: 12202289.","DOI":"10.1176\/appi.ajp.159.9.1606"},{"key":"2022012116474515400_i2168-9709-12-1-37-b45","doi-asserted-by":"crossref","unstructured":"Yang SH, McNeely MJ. Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone. Am J Psychiatry. 2002; 159(8): 1435. DOI: 10.1176\/appi.ajp.159.8.1435. PubMed PMID: 12153844.","DOI":"10.1176\/appi.ajp.159.8.1435"},{"key":"2022012116474515400_i2168-9709-12-1-37-b46","doi-asserted-by":"crossref","unstructured":"Honigberg MC, Bui MP, Coconcea C. A case of ziprasidone associated with acutely worsened diabetes mellitus. Psychosomatics. 2013; 54(3): 304- 5. DOI: 10.1016\/j.psym.2012.08.011. PubMed PMID: 23680062.","DOI":"10.1016\/j.psym.2012.08.011"},{"key":"2022012116474515400_i2168-9709-12-1-37-b47","doi-asserted-by":"crossref","unstructured":"L\u00e9tourneau G, Abdel-Baki A, Dubreucq S, Mahone M, Granger B. Hyperosmolar hyperglycemic state associated with ziprasidone treatment: a case report. J Clin Psychopharmacol. 2011; 31(5): 671- 3. DOI: 10.1097\/JCP.0b013e31822c96b7. PubMed PMID: 21881458.","DOI":"10.1097\/JCP.0b013e31822c96b7"},{"key":"2022012116474515400_i2168-9709-12-1-37-b48","doi-asserted-by":"crossref","unstructured":"Guenette MD, Hahn M, Cohn TA, Teo C, Remington GJ. Atypical antipsychotics and diabetic ketoacidosis: a review. Psychopharmacology (Berl). 2013; 226(1): 1- 12. DOI: 10.1007\/s00213-013-2982-3. PubMed PMID: 23344556.","DOI":"10.1007\/s00213-013-2982-3"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/12\/1\/37\/3006532\/i2168-9709-12-1-37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/12\/1\/37\/3006532\/i2168-9709-12-1-37.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:23:45Z","timestamp":1731687825000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/12\/1\/article-p37.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,21]]},"published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2022.01.037","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,1]]}}}